AstraZeneca Reports Farxiga Significantly Reduces Cardiovascular Death in Heart Failure Patients

AstraZeneca today announced new data from the DAPA-HF trial showing that Farxiga (dapagliflozin) significantly reduces the combined risk of cardiovascular death, worsening heart failure, or urgent heart failure visits in patients with heart failure with reduced ejection fraction. The trial demonstrated a 26% relative risk reduction in the primary composite endpoint.